• Powered by Crown Equity Holdings Inc.
      • crown-logo

        Crown Equity Holdings Inc. is publicly traded with the symbol CRWE. The Company primarily provides and offers advertising, branding, marketing solutions and services to boost customer awareness, as well as merchant visibility as a worldwide online multi-media publisher. For list of services offered click here

Post on CRWE World Login
logo New York, UNITED STATES
header-img
  • Home
  • News
  • World
      • World News
      • Español
  • Politics
      • U.S. Legislators
      • Political News
  • Sports
  • Business
      • Markets
      • Hottest Stocks Today
      • CRWEWorld Stocks
      • Blockchain
      • Regulatory
      • Accounting
      • Fundraising Campaigns
      • IPOs
      • Money
      • Career
  • Tech
      • Tech
      • Science
  • Living
      • Arts & Entertainment
      • Family
      • Food
      • Pets
      • Seniors
      • Fashion/Fitness
      • Home & Garden
  • Health
      • Health
      • Pharma & Biotech
  • Opinion
      • Finance
      • Law
      • Healthcare
      • Cannabidiol (CBD)
      • Fashion
      • Podcasts
      • Tech
      • Music
  • Travel
  • Local
      • News
      • Trending Now
      • Real Estate
      • Coupons & Deals
      • Business Directory
  • Jobs
  • More
      • Business 2 Business
      • Press Releases
      • Press Releases Pricing
      • News from GlobeNewswire
      • News from PR Newswire
      • News from Business Wire
      • News from Accesswire
      • Video Channels
      • Beauty
      • Business
      • Comedy
      • Entertainment
      • Fashion
      • Featured
      • Health
      • Instructional
      • News
      • Politics
      • Sports
      • Technology
      • Entertainment
      • Horoscope
      • Sudoku
      • Crossword
      • Games
      • Chat
      • Affiliate | How It Works
      • Join CRWE WORLD Affiliate Program
      • CRWE WORLD Advertising Services Rate
      • Crown Equity Holdings' Overview
      • CRWEWorld Real-Time Global Visitors
      • Content Delivery Solution
        • Contact Us
  • More

Change City


-- OR --
load
load
/assets/img/hottest3.png
/assets/img/hottest3.png

/assets/img/reef2.png
/assets/img/red-line.jpg
/assets/img/reef.png
  • Home
  • Articles
  • News Provided by PR Newswire
21ьз╕ Cweather-icon
/assets/img/hottest3.png
/assets/img/hottest3.png

/assets/img/reef2.png
/assets/img/red-line.jpg
/assets/img/reef.png

BAL Pharma reports H1FY22 results with 290% growth in PAT, led by strong performance of its API business

News Provided by PR Newswire2021-11-15
17 Views

BAL Pharma reports H1FY22 results with 290% growth in PAT, led by strong performance of its API business

 
[15-November-2021]
 

BENGALURU, India, Nov. 15, 2021 /PRNewswire/ -- BAL Pharma, a fully integrated pharmaceutical company specialized in Prescription Drugs, Generics, pharma intermediates, and Bulk Actives has announced its results for the second quarter and half year ended on 30th September 2021.

Financial Highlights – Q2 & H1FY22

Standalone Financial

INR Mn


Q2FY22

Q2FY21

YoY

H1FY22

H1FY21

YoY

Revenue

679.1

646.6

5%

1390.5

1172.1

19%

EBITDA

73.1

78

-6%

150.5

140.1

7%

PAT

30.5

15.3

99%

45.8

31.7

44%

The Company has delivered an all-round performance for H1FY22 with Revenue registering a growth of 19%, EBITDA grew by 7% and PAT grew by 44%. Companies API's business has been witnessing strong momentum which is driving overall growth of its standalone business. Company's standalone business comprises of majority of operating business.

Consolidated Financials

INR Mn


Q2FY22

Q2FY21

YoY

H1FY22

H1FY21

YoY

Revenue

677.3

646.2

5%

1386.9

1169

19%

EBITDA

68.8

71.6

-4%

145

124

17%

PAT

13.9

4.9

184%

30.4

7.8

290%

EPS

0.97

0.3

223%

2.11

0.6

252%

Financial Highlights- H1FY22

  • Revenue- Strong contribution from API business led to Revenue growth of 19% YoY. Such overall Revenue growth was on account of non-covid therapeutic segments and robust demand both in the domestic and international markets.
  • EBITDA increased by 17% YoY to INR 145 mn in H1FY22. EBITDA margins remained stable at 10.5%, Although bottlenecks on supply chain logistics have been gradually reducing, higher freight rates and higher Raw material costs kept EBITDA margin under check. As a result, Gross margins have witnessed softening of 200bps YoY in H1FY22.
  • PAT increased by 290% YoY to INR 30.4mn in H1FY22. Better operating leverage and lower overheads led to overall increase in PAT. Company has reduced their debt in H1FY22 which resulted into lower interests costs – down by 6% YoY in H1FY22 and by 18% YoY in Q2FY22.

API Business:

  • API segment revenue reported an increase of 45% YoY to INR 818.1 mn in H1FY22. Share of API in total revenue increase to 60% in H1FY22 from 49% in H1FY21.
  • API exports witnessed a robust growth of 71% YoY for H1FY22; The Company exports its API across various regions with Canada, Slovenia, Hungary, Japan , Mexico, Turkey being the top destinations.
  • Exports: Domestic mix was 64:36 in H1FY22 versus 44:66 in H1FY21.
  • Gliclazide being an API used for treating Diabetes has been an important contributor in the company's earnings. Top 5 API's contributed nearly 94% of API's revenue in H1FY22.
  • Total Order book for API's remains strong at INR 300 mn as on H1FY22, with New Launches in such as Alfuzosin for prostate enlargement, and Dabigatran under scale up for cardiac care.

Formulations Business:

  • Formulations segment remained marginally subdued at INR 552mn in H1FY22. However, Domestic Formulations have been witnessing positive momentum and has reported 13% growth YoY.
  • On the domestic front, the company is in the process of launching Dapagliflozin under the brand name Dapaten which is an anti-diabetic drug. With this, BAL Pharma further consolidates its market share in Diabetes as a Therapeutic segment
  • Domestic to exports was at 30:70 in H1FY22 versus 25:75 in H1FY21.
  • Order book for FDF stands at INR 200mn as on H1FY22. With the new launches and strengthening medical representative team in domestic market would continue the positive trajectory of domestic formulations market.

Commenting on financial results, Mr. Shailesh Siroya, Managing Director, BAL Pharma said, "The financial performance for H1FY22 has been quite encouraging for especially on API front. Post easing of Covid related supply chain and logistical issues, the company has been able to report a strong recovery in growth. On API front, export markets were quite buoyant and has witnessed significant improvement over previous year. The Company would keep focussing on key therapeutic areas affecting Lifestyle disorders, and Exports are expected to drive the growth momentum going head."

"It was tactically decided to restrict export of formulations in Q2FY22 due to unfavourable market conditions. Higher raw material costs, freight costs made it uneconomical to take FDF export orders. On Formulations front, company has been continuously focussing on improving Domestic market share. Domestic formulations market has been improving traction on continuous basis. Domestic FDF grew by 13% for H1FY22 and 16% QoQ basis. Company has laid out an outlay to improve market share in domestic formulations market by strengthening medical representative team and have new product launches over period of time. BAL Pharma plans to launch Gliclazide MR 30 and 60 mg in the EU market, and is expected to file dossier in Q1FY23. Though Africa and Latin America remains the dominant market for export formulations, the company is targeting increasing its presence in various other geographies like Southeast Asia and CIS countries."

"Our Strategy over medium to long-term remains to focus on API exports and  Domestic formulations and simultaneously strengthening our balance sheet as well. Our product opportunities are encouraging and we expect demand to remain buoyant going ahead in the current fiscal year".

About BAL Pharma Ltd (BPL)

BAL Pharma Limited (BSE: 524824) (NSE: BALPHARMA) is a fully integrated pharmaceutical company specialized in Prescription Drugs, Generics, pharma intermediates and Bulk Actives. BAL Pharma's focused therapeutic areas are oncology, diabetes, gastroenterology, and dermatology, The Company is one of the largest producers and exporters of Gliclazide, a medicine to treat type-2 diabetes. BAL Pharma's niche APIs and FDFs are produced at world class manufacturing facilities located at Karnataka, Maharashtra, Rajasthan and Uttarakhand. The Company exports APIs to Europe, Australia, Japan, Far East, Canada, Latin America, Africa, Middle East and other World markets. Its FDFs are exported to Semi-regulated, Non-regulated market, and a select regulated market, besides having a robust domestic presence. Backed by strength in Research and Development, and strong infrastructure, BAL Pharma is poised to become a significant company in the pharmaceutical industry.

Forward-Looking Statement:

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. BAL Pharma Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.


Company Codes: Bombay:524824, Bombay:BALPHARMA.BO, India:BALAXI.NS, India:BALPHARMA, India:EQBALPHARMA


© 2021 PR Newswire. All Rights Reserved.

The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.


Rocket Lab (Nasdaq: RKLB) Successfully Raises Orbit a Fourth Time For NASA's CAPSTONE Moon Mission



/assets/img/Reliance-Law-Firm.png

/assets/img/cw-stocks.png

/assets/img/wysh-jewels.png

/assets/img/Mars-Parachute-2.png

/assets/img/crweworld-podcast.jpg
Sponsored
Also read
Performance Shipping Inc. Announces New Loan Facility With Piraeus Bank S.A. to Finance Acquisition of Sixth Aframax Tanker
XPeng Announces Vehicle Delivery Results for June and Second Quarter 2022
Invitation - Presentation of Sandvik's report of the second quarter 2022
Puhui Wealth Investment Management Co., Ltd. Announces Financial Results for the Six Months Ended December 31, 2021
NIO Inc. Provides June and Second Quarter 2022 Delivery Update
Banc of California Announces Schedule of Second Quarter 2022 Earnings Release and Conference Call
North Atlantic Acquisition Corp. Announces Termination of Business Combination Agreement with TeleSign, Inc.
The Board of Directors of NoHo Partners Plc has decided on a directed share issue as a part of the acquisition of all the shares in Sea Horse Oy


Post on CRWE WorldSign Up for Free E-mail Updates
  • Real Estate Eagle Firm, Real Estate
  • Authentic Dominican Larimar & Amber Stone Jewelry
  • Share knowledge and ideas about stocks on CRWE World Stocks
Signup for free email updates
/assets/img/wall-street-rect2.png
/assets/img/wall-street-sq.png



Join with us
Live Traffic Feed
About CrweWorld
  • About Us
  • Privacy Policy
  • Terms & Conditions
  • Finance Disclaimer
  • Jobs
Subscribe for newsletter
3+2
Contact Info
  • contact@crweworld.com

  • P: (702) 683-8946

  • P: (702) 810-0178

  • 11226 Pentland Downs St, Las Vegas, NV 89141

Tweets by CrweWorld
Tweets by @CrweWorld
  • © 2022 crweworld.com
ad1

/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

ad2

/assets/images/ad/content-delivery-solution.jpg

 

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure

CLICK HERE FOR MORE INFORMATION

ad3

/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

/assets/images/ad/crwetube.png

Share your videos. Upload your videos for free on CRWETube

www.CRWETube.com

ad5

/assets/images/ad/ad4.png

 

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

Advertisements

/assets/images/ad/crwe_tech.jpg

Your Technology Source, Your Technology Team

Server Maintenance, Web Development, Mobile Application Solutions, SEO Services and more

Contact Us: contact@crwetech.com

www.CRWETech.com

/assets/images/ad/content-delivery-solution.jpg

 

Our content delivery solution through CRWE WORLD, CRWE Press Release and CRWE Tube gives corporations and businesses a vehicle to expand their exposure

CLICK HERE FOR MORE INFORMATION

/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

/assets/images/ad/crwetube.png

Share your videos. Upload your videos for free on CRWETube

www.CRWETube.com

/assets/images/ad/ad4.png

 

Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com

www.CRWEWorld.com

CRWE WORLD Advertising Services RateJoin CRWE WORLD Affiliate Program